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Objectives: Ipilimumab improved the survival of advanced melanoma patients in 
phase III trials (MDX010-20 [previously treated patients] and CA184-024 [treatment 
naïve patients]). Uncertainty exists, however, whether this benefit can be translated 
to real-world clinical practice. We investigated the use and survival outcomes of 
ipilimumab in The Netherlands. MethOds: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Survival outcomes 
(overall survival [OS] and one-year survival) in patients receiving ipilimumab in 
clinical practice were assessed using Kaplan-Meier estimates, and were compared 
with outcomes of pivotal trials and outcomes of real-world patients diagnosed 
before the introduction of ipilimumab (2003-2011; stage IV only) using data from 
the Dutch Comprehensive Cancer Centres. Results: From 2012-2015, 545 patients 
received at least one dose of ipilimumab in real-world practice (65% received four 
dosages; median follow-up 4.6 months; data cut-off March 9, 2015). Ipilimumab 
was most frequently prescribed in the second line (60%), followed by the first (31%), 
third (8%), and fourth line (2%), respectively. Median OS was 7.7 months (IQR:3.6-NR) 
and one-year survival was 40%. This is somewhat lower than in the pivotal trials, 
which may be due to differences in baseline characteristics and time of follow-up 
(MDX010-20: median follow-up 27.8 months, median OS 10.1 months, one-year 
survival 46%; CA184-024: median follow-up 11.0 months, median OS 11.2 months, 
one-year survival 48%). However, the survival was higher compared to the survival 
in the period before the introduction of ipilimumab (2003-2011: median OS 6.8 
months [IQR:3.3-18.5], one-year survival 33%). cOnclusiOns: Melanoma survival 
has improved since the introduction of ipilimumab. Although survival was some-
what lower in real-world compared to pivotal trials, a survival benefit was observed 
in Dutch real-world clinical practice.
PCN63
WheN “alIve aFter 5 yearS” doeS Not meaN “Cured”: INterNatIoNal 
PatterNS IN CaNCer 10- to 20- year relatIve SurvIval rateS
Martin A, Martin C
Crystallise Ltd., London, UK
Objectives: Traditionally, patients who survive 5 years from diagnosis of cancer 
are considered to be cured. More recent analysis of adjusted mortality rates sug-
gests this assumption may not be valid. We sought to identify data on relative 
survival at 10 to 20 years for common cancers to determine which showed a 
continuing increase in mortality beyond 5 years. MethOds: National or regional 
cancer databases reporting net or relative survival beyond 5 years from diagno-
sis were identified, with 5- and 10-year data available from England and Wales, 
Scotland, the USA, Switzerland and Slovakia; 5-, 10- and 15-year data from Norway; 
and 5-, 10-, 15- and 20-year data from Germany and Sweden. The percentage 
decrease in net survival at each 5-year step was calculated at 10, 15 and 20 years 
to identify where there was a persistent increase in all-cause mortality above 
expected for the age- and sex-adjusted cancer-free population. Results: Regional 
setting had a large impact on relative survival for each type of cancer. However, 
oropharyngeal, head and neck, liver, lung, pancreatic and ovarian cancers, chronic 
lymphocytic leukaemia, mesothelioma, multiple myeloma, and Kaposi’s sarcoma 
consistently showed between a 10% and 70% further decrease in relative survival 
at 10 compared with 5 years. A further 10% or greater decrease in relative sur-
vival was seen between 10 and 20 years from diagnosis for head and neck, lung, 
laryngeal and prostate cancer, and was around 40% lower than population norms 
at 20 years for people with multiple myeloma. cOnclusiOns: When modelling 
the impact of treatments for cancer, it is important to consider the whole period 
of increased risk of mortality. For certain cancers, in particular multiple myeloma, 
lung, prostate and laryngeal cancer, this may require a time horizon of 20 years 
or longer.
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Objectives: New drugs for advanced melanoma showed promising results in piv-
otal trials; however, uncertainty exists regarding their value in real-world clinical 
practice. We investigated real-world treatment patterns and outcomes of advanced 
melanoma in The Netherlands. MethOds: We retrieved data from the population-
based Dutch Melanoma Treatment Registry (DMTR). The DMTR includes all Dutch 
patients with unresectable stage IIIc/IV melanoma. Detailed data were prospectively 
collected from start of diagnosis until death or loss to follow-up. Real-world treat-
ment patterns and outcomes (overall survival [OS], one-year survival and time-to-
next-treatment [TTNT]) were assessed in patients receiving systemic treatment 
Weights (IPCW), and Iterative Parameter Estimation (IPE). To determine acceptance 
of these techniques in Australia, Public Summary Documents (PSDs) reporting on the 
Pharmaceutical Benefits Advisory Committee’s (PBAC’s) decision-making in oncol-
ogy were reviewed. MethOds: Oncology PSDs were examined, and the method of 
adjustment (if any), PBAC concerns and outcome were assessed. Results: Thirty-
one submissions included trials allowing crossover; 16 (52%) presented adjusted 
estimates of OS. Common indications were: renal cell carcinoma, non-small cell 
lung cancer (NSCLC), melanoma, colorectal cancer (CRC), and pancreatic neuroendo-
crine tumour. The most common method was RPSFT (11 products), followed by IPCW 
(4 products). IPE, marginal structural modelling, and a two-stage Weibull approach 
were each reported once. The RPSFT approach appeared to raise fewer concerns 
than the IPCW, usually because the IPCW correction was considered less reliable 
when a high proportion of patients crossed-over. In NSCLC and CRC, the PBAC con-
sidered unadjusted crossover to be appropriate and reflect a relevant comparison 
between first- and second-line therapy. Only five PSDs reported results of more 
than one method. The PBAC expressed a preference to see a range of approaches 
and a clearly justified selection of the most appropriate method. cOnclusiOns: A 
range of adjustment techniques were used to support submissions in Australia, with 
RPSFT being most common. It is important to clearly justify the need for adjustment 
and the selection of the most appropriate technique.
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Objectives: In oncology an important parameter of safety is the potential treat-
ment error in hospitals. The hypothesis which is being analyzed in the underlying 
work is the potential benefit of hospitals from a safety reduction through fix-
dose ready to use subcutaneous therapies in comparison to intravenous therapies 
with trastuzumab and rituximab. MethOds: For the calculation of risk levels the 
Failure Mode and Effect Analysis (FMEA) approach was being applied. Within that 
approach the critical treatment path is followed and risk classification for each 
individual step is being estimated. For the oncology and hematology administra-
tion there were 35 different risk steps assessed. The study was executed in 17 
hematology and 16 breast cancer centers in Italy. Results: When the risk classes 
are calculated there were eight high risk areas identified for the administration 
of an intravenous therapy in hematology or oncology, 13 areas would be defined 
as having a median risk and 14 areas as having a low risk classification (total risk 
areas: n= 35). When the new subcutaneous formulation would be applied 23 dif-
ferent risk levels could be completely eliminated (65% reduction). Including those 
eliminations important high risk classes such as the following were included: 
dose calculation, preparation and package labeling, preparation of the access to 
the vene and pump infusion preparation and infusion monitoring. The overall risk 
level for the intravenous administration was estimated to be 756 (ex-ante) and 
could be significantly reduced by 70% (ex-post). The potential harm compensation 
for errors related to the pharmacy would be decreased from 234’271 € for eight 
risk classes to only 3 risk classes. cOnclusiOns: The use of a subcutaneous 
administration of trastuzumab (breast cancer) and rituximab (hematology) might 
lower the risk of administration and treatment errors for patients and could hence 
indirectly have a positive financial impact for hospitals.
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Objectives: There is a paucity of study to examine the relationship between 
metformin use and hepatocellular carcinoma (HCC) specific survival or recur-
rence. We, therefore, conducted a nationwide population-based study in the 
patients with HCC who underwent curative resection to investigate whether 
metformin use would reduce mortality and recurrence rate. MethOds: The 
study population initially included 105,367 adults who had a primary diagno-
sis of HCC (International Classification of Diseases, 10th revision, C22) from the 
Korea Center Cancer Registry between 1 January 2005 and 31 December 2011. 
The primary outcome was HCC-specific survival. We obtained HCC deaths from 
the National Population Registry of the Korea National Statistical Office through 
December 31, 2013, with the use of a unique personal identification number. The 
secondary outcome was tumor recurrence during follow-up periods from National 
Health Insurance Service. Results: The HCC-related survival or recurrence-free 
was significantly higher in the metformin user group than in the metformin non-
user group during the follow-up period. In unadjusted analyses, compared to 
non-metformin group, metformin group showed a significant lower risk of HCC-
specific death (hazard ratio (HR), 0.40; 95% Confidence interval (CI), 0.32-0.51). 
After multivariable adjustments for clinical covariates, metformin group still had 
a significantly lower risk of events as compared with non-metformin group (HR, 
0.38; 95% CI, 0.30-0.49). The adjusted risk for recurrence was also significantly 
lower in metformin group (HR, 0.41; 95% CI, 0.33-0.52) compared with that of non-
metformin group. cOnclusiOns: Among patients of HCC cohort treated with 
curative hepatic resection, metformin use was associated with improvement of 
HCC-specific mortality and recurrence risk.
